TaiMed Biologics Inc (中裕新藥) yesterday downplayed concerns about the company’s choice of distribution partner for its new HIV/AIDS drug TMB355, citing a robust business plan and advantages in tax management.
The company last month announced that it had inked an exclusive 12-year contract with Montreal-based Theratechnologies Inc to market its new drug in the US and Canada.
Analysts were downbeat on the partnership, casting doubts on the Canadian company’s ability to market the new drug compared with large companies.
“While Theratechnologies might not be a big name, marketing our product would be the company’s top priority,” TaiMed chief financial officer James Chen (陳怡成) said at an investors’ conference in Taipei.
Chen said larger companies might not be as motivated in marketing TMB355, as they tend to have many products in the mix, including their own new drug development initiatives.
He said that TMB355 would benefit from Theratechnologies’ history of working with HIV specialists across North America as a distributor of EGRIFTA — a treatment to reduce excess abdominal fat in HIV patients with lipodystrophy.
Chen added that the payment terms and timetable offered by Theratechnologies would yield more tax gains based on International Financial Reporting Standards 15 (IFRS), in addition to benefits from an agreement signed between Taiwan and Canada.
As for concerns over lower-than-expected payment terms for TMB355, Chen said that TaiMed retains a high level of control in how the new drug would be marketed in the future.
“You will see some of our peers booking cash income immediately, but their partners have effectively taken control of the drugs through licensing deals,” he said.
By contrast, once TMB355 gains approval from the US Food and Drug Administration (FDA), the company will seek other distribution partners for larger markets such as China, Chen said.
“Drug resistance is among the most challenging aspects of developing treatments for HIV/AIDS, and the situation is made worse when patients do not follow the regimen and administer the required injections daily,” he added.
TMB355 requires only a single injection daily, and its only competitor on the market is Fuzeon, which requires multiple daily injections, with 98 percent of patients using the drug reporting adverse side effects on their injection sites, Chen said.
Meanwhile, an intravenous injection of TMB355 has entered third-phase clinical trials, while an intramuscular and intradermal injection variant of the drug is undergoing first and second-phase trials.
The drug is expected to be approved by the US FDA in the first quarter of next year, he added.
The global market for HIV/AIDS treatments is expected to grow 7 percent this year to NT$500 billion, the company said, adding that more than 35 million people are infected with HIV worldwide, and less than 30 percent receive treatment.
Last year, the company reported an operating loss of NT$471 million, or losses of NT$2.16 per share.
RUN IT BACK: A succesful first project working with hyperscalers to design chips encouraged MediaTek to start a second project, aiming to hit stride in 2028 MediaTek Inc (聯發科), the world’s biggest smartphone chip supplier, yesterday said it is engaging a second hyperscaler to help design artificial intelligence (AI) accelerators used in data centers following a similar project expected to generate revenue streams soon. The first AI accelerator project is to bring in US$1 billion revenue next year and several billion US dollars more in 2027, MediaTek chief executive officer Rick Tsai (蔡力行) told a virtual investor conference yesterday. The second AI accelerator project is expected to contribute to revenue beginning in 2028, Tsai said. MediaTek yesterday raised its revenue forecast for the global AI accelerator used
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has secured three construction permits for its plan to build a state-of-the-art A14 wafer fab in Taichung, and is likely to start construction soon, the Central Taiwan Science Park Bureau said yesterday. Speaking with CNA, Wang Chun-chieh (王俊傑), deputy director general of the science park bureau, said the world’s largest contract chipmaker has received three construction permits — one to build a fab to roll out sophisticated chips, another to build a central utility plant to provide water and electricity for the facility and the other to build three office buildings. With the three permits, TSMC
TEMPORARY TRUCE: China has made concessions to ease rare earth trade controls, among others, while Washington holds fire on a 100% tariff on all Chinese goods China is effectively suspending implementation of additional export controls on rare earth metals and terminating investigations targeting US companies in the semiconductor supply chain, the White House announced. The White House on Saturday issued a fact sheet outlining some details of the trade pact agreed to earlier in the week by US President Donald Trump and Chinese President Xi Jinping (習近平) that aimed to ease tensions between the world’s two largest economies. Under the deal, China is to issue general licenses valid for exports of rare earths, gallium, germanium, antimony and graphite “for the benefit of US end users and their suppliers
Dutch chipmaker Nexperia BV’s China unit yesterday said that it had established sufficient inventories of finished goods and works-in-progress, and that its supply chain remained secure and stable after its parent halted wafer supplies. The Dutch company suspended supplies of wafers to its Chinese assembly plant a week ago, calling it “a direct consequence of the local management’s recent failure to comply with the agreed contractual payment terms,” Reuters reported on Friday last week. Its China unit called Nexperia’s suspension “unilateral” and “extremely irresponsible,” adding that the Dutch parent’s claim about contractual payment was “misleading and highly deceptive,” according to a statement
RSS